Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVR6OM)

• Drug Name: Flotetuzumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute biphenotypic leukaemia	2B33.4	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMVR6OM

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin 3 receptor alpha (IL3RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tagraxofusp	DM9HQ5U	Acute myeloid leukaemia	2A60	Approved	[4]
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[5]
Talacotuzumab	DMARVFG	Acute myeloid leukaemia	2A60	Phase 2	[3]
MB-102	DMLPNVS	Acute kidney injury	GB60	Phase 2	[3]
4SCAR19 and 4SCAR123	DMYPQT4	B-cell lymphoma	2A86	Phase 1/2	[6]
SAR440234	DM6M8O4	Acute myeloid leukaemia	2A60	Phase 1/2	[7]
CD123-specific gene-engineered T cells	DMHOWU5	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[9]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[10]
Anti-CD123-CAR-transduced T cells	DMFV6TY	leukaemia	2A60-2B33	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT03739606) Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [6] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [7] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [8] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [9] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [10] ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
• [11] ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies